Back

Misclassification of a frequent loss of function variant from PMS2CL pseudogene as a PMS2 variant in Brazilian patients

Segura, A. V. C.; Silva, S. I. O. d.; Santiago, K. M.; Brianese, R. C.; Carraro, D. M.; Torrezan, G. T.

2024-03-27 genetic and genomic medicine
10.1101/2024.03.26.24304914 medRxiv
Show abstract

PMS2, a Lynch Syndrome gene, presents challenges in genetic testing due to the existence of multiple pseudogenes. This study aims to describe a series of cases harboring a rare LoF variant in the PMS2CL pseudogene that has been incorrectly assigned to PMS2 with different nomenclatures. We reviewed data from 647 Brazilian patients who underwent multigene genetic testing at a single center to identify those harboring the PMS2 V1:c.2186_2187delTC or V2:c.2182_2184delACTinsG variants, allegedly located at PMS2 exon 13. Gene-specific PCR and transcript sequencing was performed. Among the 647 individuals, 1.8% (12) carried the investigated variants, with variant allele frequencies ranging from 15 to 34%. By visually inspecting the alignments, we confirmed that both V1 and V2 represented the same variant and through gene-specific PCR and PMS2 transcript analysis, we demonstrated that V1/V2 is actually located in the PMS2CL pseudogene. Genomic databases (ExAC and gnomAD) report an incidence of 2.5% - 5.3% of this variant in the African population. Currently, V1 is classified as "uncertain significance" and V2 as "conflicting" in ClinVar, with several laboratories classifying them as "pathogenic". We identified a frequent African PMS2CL LoF variant in the Brazilian population that is misclassified as a PMS2 variant. It is likely that V1/V2 have been erroneously assigned to PMS2 in several manuscripts and by clinical laboratories, underscoring a disparity-induced matter. Considering the limitations of short-read NGS differentiating between certain regions of PMS2 and PMS2CL, using complementary methodologies is imperative to provide an accurate diagnosis.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Journal of Medical Genetics
28 papers in training set
Top 0.1%
22.8%
2
The Journal of Molecular Diagnostics
36 papers in training set
Top 0.1%
10.5%
3
European Journal of Human Genetics
49 papers in training set
Top 0.1%
10.5%
4
Human Mutation
29 papers in training set
Top 0.1%
9.2%
50% of probability mass above
5
PLOS ONE
4510 papers in training set
Top 25%
6.9%
6
Scientific Reports
3102 papers in training set
Top 23%
4.9%
7
Cancers
200 papers in training set
Top 2%
2.9%
8
American Journal of Medical Genetics Part A
17 papers in training set
Top 0.1%
2.6%
9
Genetics in Medicine
69 papers in training set
Top 0.6%
2.1%
10
Frontiers in Genetics
197 papers in training set
Top 3%
2.1%
11
Genes
126 papers in training set
Top 0.6%
2.1%
12
Orphanet Journal of Rare Diseases
18 papers in training set
Top 0.3%
1.7%
13
International Journal of Molecular Sciences
453 papers in training set
Top 7%
1.7%
14
npj Genomic Medicine
33 papers in training set
Top 0.4%
1.7%
15
BMC Genomic Data
12 papers in training set
Top 0.1%
1.5%
16
The American Journal of Human Genetics
206 papers in training set
Top 3%
1.0%
17
Journal of Clinical Medicine
91 papers in training set
Top 6%
0.8%
18
Frontiers in Molecular Biosciences
100 papers in training set
Top 4%
0.8%
19
Frontiers in Oncology
95 papers in training set
Top 3%
0.8%
20
Muscle & Nerve
10 papers in training set
Top 0.4%
0.8%
21
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 11%
0.7%
22
Frontiers in Medicine
113 papers in training set
Top 9%
0.5%
23
Modern Pathology
21 papers in training set
Top 0.6%
0.5%
24
Human Molecular Genetics
130 papers in training set
Top 5%
0.5%
25
Journal of Genetics and Genomics
36 papers in training set
Top 3%
0.5%